Khadijah Al-Tall
Papers
2
Total Citations
23
H-Index
2
About
Dr. Khadijah Al-Tall is a pioneering researcher at the intersection of nanotechnology and biomedical engineering, with a primary focus on developing innovative biosensing platforms for cancer diagnostics. Her most significant contribution is the design of living nano-robots—engineered, nonpathogenic *E. coli* bacteria equipped with natural bio-nano-sensory systems—that selectively detect vascular endothelial growth factor (VEGF), a key biomarker overly expressed by tumor cells during angiogenesis. This groundbreaking work, published in her highly cited 2017 paper in *Sensors* (21 citations), introduces a novel, self-detection method that could revolutionize early cancer diagnosis by enabling real-time, targeted identification of angiogenic factors. Dr. Al-Tall’s research bridges synthetic biology and nanomedicine, offering a biocompatible and scalable approach to tumor detection. Her meticulous attention to scientific accuracy is evident in her erratum (2 citations), which corrected a co-author’s name, reflecting her commitment to precision in publication. With her work laying the foundation for next-generation theranostic agents, Dr. Al-Tall stands as a rising leader in the field, inspiring future applications in personalized oncology and smart drug delivery systems.
Research Focus
Key Achievements
Top Papers
- 1
- 2